New study to reveal hidden immune effects of common leukemia drug

NCT ID NCT06992934

Not yet recruiting Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal is to gather information that could help design better ways to prevent cancer relapse after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gilteritinib
What this could lead to: If successful, this could help doctors understand how to better combine targeted drugs with cell therapies to prevent cancer relapse after transplant.
What could go wrong: This is a very small, early observational study with only 10 participants. It is not designed to test if gilteritinib works, only to explore its effects on immune cells, so results may not lead to direct treatment changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Locations

CHU de NICE

Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.